Engitix Ltd., of London, closed a £5 million (US$6.4 million) series A financing, led by a private investor. The company, spun out of the Institute for Liver and Digestive Health at University College London in 2016, is working to develop a pipeline of candidate drugs targeting liver fibrosis and liver and pancreatic cancers.